Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry
- 1 July 2002
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 16 (7) , 1381-1389
- https://doi.org/10.1038/sj.leu.2402512
Abstract
The clinical significance of WT1 gene expression at diagnosis and during therapy of AML has not yet been resolved. We analysed WT1 expression at presentation in an unselected group of 47 childhood AML patients using real-time quantitative reverse-transcription PCR. We also showed that within the first 30 h following aspiration RQ-RT-PCR results were not influenced by transportation time. We observed lower levels of WT1 transcript in AML M5 (P = 0.0015); no association was found between expression levels and sex, initial leukocyte count and karyotype-based prognostic groups. There was significant correlation between very low WT1 expression at presentation and excellent outcome (EFS P = 0.0014). Combined analysis of WT1 levels, three-colour flow cytometry residual disease detection and the course of the disease in 222 samples from 28 children with AML showed remarkable correlation. Fourteen patients expressed high WT1 levels at presentation. In eight of them, who suffered relapse or did not reach complete remission, dynamics of WT1 levels clearly correlated with the disease status and residual disease by flow cytometry. We conclude that very low WT1 levels at presentation represent a good prognostic factor and that RQ-RT-PCR-based analysis of WT1 expression is a promising and rapid approach for monitoring of MRD in approximately half of paediatric AML patients.Keywords
This publication has 22 references indexed in Scilit:
- The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cellsThe EMBO Journal, 2001
- Wilms Tumor and the WT1 GeneExperimental Cell Research, 2001
- The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantationBone Marrow Transplantation, 2000
- Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocolEuropean Journal of Haematology, 1999
- Wilms' Tumor Gene Product WT1 Arrests Macrophage Differentiation of HL-60 Cells Through Its Zinc-Finger DomainBiochemical and Biophysical Research Communications, 1999
- Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemiaLeukemia, 1998
- Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation programOncogene, 1998
- Expression of the Wilms' Tumor Suppressor Gene, WT1, Is Upregulated by Leukemia Inhibitory Factor and Induces Monocytic Differentiation in M1 Leukemic CellsBlood, 1998
- WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemiaBlood, 1994
- Downregulation of Wilms' tumor gene (wt1) during myelomonocytic differentiation in HL60 cellsBlood, 1994